ANGLE: Clinical study shows detection of CTCs in glioblastoma patients

ANGLE plc (“the Company”)

CLINICAL STUDY SHOWS DETECTION OF CTCS IN GLIOBLASTOMA PATIENTS

GBM CTC isolation only possible with Parsortix label-free methodology

Data presented at the 7^th ACTC meeting

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce the presentation of new data from a proof-of-concept study in glioblastoma at the 7th Advances in Circulating Tumour Cells (ACTC) meeting, held 24–27 September 2025 in Thessaloniki, Greece.

The poster entitled ‘Detection of circulating tumour cells from glioblastoma patients’ blood samples’ reports on data from 15 newly diagnosed, treatment-naïve glioblastoma (GBM) patients whose blood was processed using the Parsortix^® system and CellKeep™ slides. This approach has the potential to allow for minimally invasive, repeatable monitoring in patients with GBM.

Key findings:

• CTCs were detected in 60% of patients and CTC clusters, which are known to have high metastatic potential, were observed in 78% of CTC-positive patients. This is particularly significant given that ctDNA is observed in less than 10% of glioma patients possibly due to failure to cross the blood-brain barrier¹
• All CTCs detected exhibited a mesenchymal phenotype, consistent with the biology of GBM, which would not be detectable using traditional CTC technologies that rely on cell surface markers to isolate CTCs
• Extracellular vesicles (EVs) were observed in 73% of subjects, further supporting the potential of liquid biopsy for dynamic monitoring in GBM
• The ability to harvest and analyse CTCs and EVs from a single blood sample opens new avenues for a multi-analyte, minimally invasive, real-time assessment of tumour biology, disease progression, and response to therapy in GBM patients

ANGLE’s Chief Scientific Officer, Karen Miller, commented:

"We are delighted to present our first data in GBM at the ACTC 2025 conference. These results demonstrate the capability of the Parsortix label-free system to capture and characterise CTCs in GBM where ctDNA approaches have struggled. This creates the opportunity to start monitoring GBM patients using proteomic and molecular biomarkers during their treatment, as well as support pharma companies developing new drugs for this cancer."